- About
- IgAN
- Events
- Resource Center
- Simulators
What interests you?+Help Us Enhance Your NephU ExperienceHelp Us Enhance Your NephU Experience
User experience form
Archives
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, & Outcomes In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Thank you for attending, we hope you enjoyed this webinar.
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Patient-Reported Outcomes Measures, Polycystic Kidney Disease Burden, & Outcomes In Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Background
ADPKD can negatively affect many aspects of patients’ lives including physical symptoms and limitations, psychological burden, medical costs, and work limitations. Although assessment tools have been developed to better understand the patient disease burden, many providers still underestimate this burden often leading to inadequate management and support for these ADPKD patients.1
Did You Know?
- Patients with both early and late stage ADPKD experience a significant disease burden, and this is often underestimated, especially in younger patients.
- The goal of this webinar is to more fully illustrate the ADPKD patient burden associated with varying disease severity.
- Another goal of this webinar is to determine if patient reported burden is associated with worse clinical and health-economic outcomes.
- Better understand the patient burden of ADPKD
- Determine whether patient reported outcomes predict risks of future adverse ADPKD related outcomes
- Oberdhan D et al. Kidney Med. 2024;6:100755.
Frederic F Rahbari Oskoui, MD
Professor of Medicine, Nephrology, Emory University School of MedicineEmory University School of Medicine*
Dr Frederic Rahbari is the director of Cystic Kidney Diseases Clinic at Emory University and has been a nephrologist practicing at Emory University Hospital in Atlanta, GA since 2006. Dr Rahbari attended medical school at Université de Bordeaux in France and completed a residency program at the same institution. After moving to the United States, Dr Rahbari did clinical and translational research on oxidative stress at New York Medical College and subsequently redid three years of residency training in internal medicine at St. Vincent Hospital -Columbia University College of Physicians and Surgeons. He has also completed a fellowship in nephrology at Emory University. Dr Rahbari has been a principal investigator in several PKD trials and is a member of the Scientific Advisory Committee of the Polycystic Kidney Disease Foundation.
Hannah N. Lambert, PharmD
Nephrology Medical Science LiaisonOtsuka Pharmaceutical Development & Commercialization, Inc.*Hannah N. Lambert is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization. She earned her Doctor of Pharmacy and completed her clinical residency training at Xavier University of Louisiana College of Pharmacy in New Orleans, LA. Prior to joining Otsuka, Dr Lambert was a clinical pharmacist at Ochsner Health in Digital Medicine.
*Dr Frederic Rahbari is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Hannah Lambert is an employee of OPDC.
Registration
Related Events
NephU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI) - committed supporters of the Kidney Health Community. The information provided through NephU is intended for the educational benefit of health care professionals and others who support care for those with kidney disease and other related conditions. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing NephU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by NephU. Some of the contributors may be paid consultants of OPDC and/or OAPI.©2024 Otsuka Pharmaceutical Development & Commercialization, Inc. All rights reserved. - IgAN
